期刊
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
卷 24, 期 6, 页码 987-994出版社
WROCLAW MEDICAL UNIV
DOI: 10.17219/acem/33811
关键词
arteriogenesis; proinflammatory factors; proangiogenic factors; endostatin; innovative treatment
资金
- [1749]
- Action Medical Research [1749] Funding Source: researchfish
Background. The process of collateral vessel maturation is stimulated by numerous factors affecting the endothelium and smooth muscle cells building the vessel wall. Looking for arteriogenesis stimulating factors means looking for a potential innovative heart failure treatment method in the patients unresponsive to traditional therapies. Objectives. The purpose of this study was to assess the changes in serum concentrations of pro-inflammatory factor IL-6, growth factors FGF (FGFa, FGFb, FGFbH), HGF, VEGF and endostatin in heart failure patients in relation to the coronary collaterals development stage. Material and Methods. This study included 22 patients with chronic heart failure NYHA II or III (mean age 62.5 +/- 11.6 years) and 8 control patients (mean age 58.4 +/- 10.7 years). Coronary angiography was performed and the presence and grade of collateral circulation was assessed by a four-level scale proposed by Rentrop and Cohen. The level of the studied factors was determined in the blood samples collected during the angiographic procedure. Results. The concentration of IL-6 was significantly higher in the heart failure patients than in the control group (p < 0.001) and in NYHA III vs. NYHA II patients (p < 0.02). Patients with heart failure and collaterals grade 1 or 2 exhibited higher serum concentrations of FGFbH (from p < 0.03 to p < 0.01). The serum VEGF level in NYHA III patients was significantly higher than in NYHA II individuals (from p < 0.03 to p < 0.01). Conclusions. Higher levels of IL-6 and FGFbH were observed in patients with heart failure. Collaterals formation seems to be associated with the activation of pro-inflammatory factors, growth factors and endostatin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据